HC Wainwright Lowers Personalis (NASDAQ:PSNL) Price Target to $8.00

Personalis (NASDAQ:PSNL) had its price target decreased by HC Wainwright from $11.00 to $8.00 in a report released on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Personalis’ Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($1.36) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.39) EPS, FY2028 earnings at ($0.05) EPS and FY2029 earnings at $0.35 EPS.

Several other equities research analysts have also recently weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $7.25 target price on shares of Personalis in a report on Wednesday, January 8th. Lake Street Capital raised their target price on shares of Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th.

Personalis Price Performance

Shares of NASDAQ PSNL opened at $5.01 on Monday. The stock has a market capitalization of $353.95 million, a P/E ratio of -2.98 and a beta of 1.75. Personalis has a one year low of $1.12 and a one year high of $7.20. The firm’s 50 day simple moving average is $4.93 and its two-hundred day simple moving average is $4.75.

Personalis (NASDAQ:PSNL) last issued its earnings results on Wednesday, November 6th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). The business had revenue of $25.71 million during the quarter, compared to analysts’ expectations of $20.67 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. During the same quarter in the previous year, the business earned ($0.51) EPS. As a group, equities analysts expect that Personalis will post -1.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Personalis

A number of large investors have recently made changes to their positions in PSNL. ARK Investment Management LLC raised its holdings in shares of Personalis by 11.4% during the third quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock valued at $38,120,000 after acquiring an additional 723,637 shares in the last quarter. abrdn plc bought a new position in Personalis in the 4th quarter worth $1,722,000. Walleye Capital LLC bought a new stake in shares of Personalis during the 3rd quarter valued at about $897,000. Jane Street Group LLC increased its position in shares of Personalis by 154.3% during the third quarter. Jane Street Group LLC now owns 164,281 shares of the company’s stock valued at $884,000 after buying an additional 99,671 shares during the period. Finally, Geode Capital Management LLC raised its stake in Personalis by 20.0% in the third quarter. Geode Capital Management LLC now owns 498,470 shares of the company’s stock worth $2,683,000 after buying an additional 83,068 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.